Navigation Links
Cardium Announces Agreement With UK-Based Angel Biomedical For Excellagen Supply And Planned European Market Expansion
Date:5/15/2012

myocardial ischemia due to coronary artery disease.  In addition, consistent with its capital-efficient business model, Cardium continues to actively evaluate new technologies and business opportunities.  In July 2009, Cardium completed the sale of its InnerCool Therapies medical device business to Royal Philips Electronics, the first asset monetization from the Company's biomedical investment portfolio. News from Cardium is located at www.cardiumthx.com.

Forward-Looking Statements  

Except for statements of historical fact, the matters discussed in this press release are forward looking and reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond our control and may cause actual results to differ materially from stated expectations.  For example, there can be no assurance that Angel can effectively and efficiently manufacture collagen to support Excellagen commercialization; that  we can successfully introduce Excellagen into wound care markets for the treatment of diabetic foot ulcers or other dermal wounds; that we can obtain a CE Mark for marketing and sale in the European Union and other countries recognizing CE Mark approval; that we can establish our own Device Master File with the FDA's Center for Devices and Radiological Health covering the Company's process for manufacturing Excellagen; that we can attract suitable commercialization partners for our products or that such partners will successfully commercialize our products; that our exchange listing compliance can be maintained; that our product or product candidates will not be unfavorably compared to other competitive products that may be regarded as safer, more effective, easier to use or less expensive; that results or trends observed in one clinical study or procedure will be reproduced in subsequent studies or procedures or in actual use; that clinical studies
'/>"/>

SOURCE Cardium Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Cardium and Tissue Repair Companys Excellarate Candidate for Healing Diabetic Wounds Gains Media Focus in Multiple Regions Across U.S.
2. Cardiums Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack
3. Cardium Announces Appointment of Paul A. Foster, M.D. to Lead Generx and Excellarate Late-Stage Development Activities
4. Cardium Reports on Second Quarter 2008 Highlights and Financial Results
5. Cardiums InnerCool Announces Positive Benefits of Cooling During Robotic-Assisted Prostate Surgery Published in Urology
6. Cardium Reports on Applicability of Corgentin to Stem Cell Therapies: Independent Studies Indicate that Ad5IGF-1 Potentiates Stem Cells to Improve Cardiac Function After Heart Attack
7. Cardium Announces Completion of Patient Recruitment in Phase 2b Clinical Trial of Excellarate(TM) for the Potential Treatment of Diabetic Foot Ulcers
8. Cardium Completes Initial Patient Evaluation Period for MATRIX Phase 2b Excellarate Clinical Study
9. Cardium Reports Non-Healing Wounds Continue to Challenge Patients and Healthcare Providers
10. Cardium Presents at Tenth Annual Wound Healing: Science and Industry Conference on Matrix Wound Healing Clinical Development
11. Cardium Files FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Topical Gel and ExcellagenFX(TM) Flowable Collagen Protein-Based Matrix for Diabetic, Pressure and Venous Ulcers and Other Dermal Wounds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2015)... , Sept. 4, 2015  PTC Therapeutics, ... announce five recipients of its first-ever global awards ... Vision and Empowerment), designed to aid nonprofit organizations ... dystrophy (DMD) community. The announcement is made as ... World Duchenne Awareness Day on Monday, September 7, ...
(Date:9/4/2015)... , September 4, 2015 ... ), a clinical-stage pharmaceutical company focused on the development ... Company will participate in the upcoming Rodman & Renshaw ... September 8-10, 2015 in New York City ... Oramed, will present a corporate overview on September 9, ...
(Date:9/4/2015)... , September 4, 2015 Future ... Allergic Rhinitis drugs - new ... Where is the market for allergic rhinitis drugs ... Visiongain ,s new report shows you potential revenues ... prospects. Our 326 page report provides 273 ...
Breaking Medicine Technology:PTC Therapeutics Announces Five Winners In Its First-ever Global Duchenne Muscular Dystrophy Patient Group Award 2PTC Therapeutics Announces Five Winners In Its First-ever Global Duchenne Muscular Dystrophy Patient Group Award 3PTC Therapeutics Announces Five Winners In Its First-ever Global Duchenne Muscular Dystrophy Patient Group Award 4Oramed to Present at the Rodman & Renshaw Global Investment Conference 2Oramed to Present at the Rodman & Renshaw Global Investment Conference 3Allergic Rhinitis Drugs Market Forecast 2015-2025 2Allergic Rhinitis Drugs Market Forecast 2015-2025 3Allergic Rhinitis Drugs Market Forecast 2015-2025 4Allergic Rhinitis Drugs Market Forecast 2015-2025 5Allergic Rhinitis Drugs Market Forecast 2015-2025 6Allergic Rhinitis Drugs Market Forecast 2015-2025 7
... Globus Medical, Inc., the largest,privately held spinal ... in motion preservation technology, today announced the completion ... study. The,SECURE(R)-C device is designed to mimic the ... pain and restore function as an alternative to ...
... Siemens Healthcare and,Laboratory Corporation of America(R) Holdings ... non-exclusive agreement to discuss future,possibilities to co-develop ... of,companion diagnostics, metabolic syndrome, oncology and diabetes. ... developing new tests that,could make the biggest ...
Cached Medicine Technology:Globus Medical Completes Enrollment Of SECURE(R)-C Cervical Artificial Disc Clinical Trial 2Siemens and LabCorp Enter Agreement to Co-Develop New Clinical Diagnostic Tests 2Siemens and LabCorp Enter Agreement to Co-Develop New Clinical Diagnostic Tests 3Siemens and LabCorp Enter Agreement to Co-Develop New Clinical Diagnostic Tests 4
(Date:9/4/2015)... (PRWEB) , ... September 04, 2015 , ... ... 2014, Insight Product Development has effectively doubled the size of its annual health ... Midwest medical device and digital health startups to compete for cash and prizes ...
(Date:9/4/2015)... ... 04, 2015 , ... Mile High Connects today releases “First and Last Mile ... for sidewalks, bike paths, and other vital supports severely limit access to public transportation ... of dollars to expand public transit, there’s very little support for safe and convenient ...
(Date:9/4/2015)... (PRWEB) , ... September 04, 2015 , ... The Providence ... to learn more about their fertility and egg freezing. , Date and Time: October ... 6PM to 7PM , This hip and informative event will discuss the basics of ...
(Date:9/4/2015)... ... 2015 , ... Georgia Insurance Advisors, a locally owned insurance ... provide for the family of Grace, a young local girl battling restrictive cardiomyopathy. ... to diastolic dysfunction – the inability to adequately move blood through the circulatory ...
(Date:9/4/2015)... ... September 04, 2015 , ... Inmar announced today ... meeting of its Product, Quality and Manufacturers, Dietary Supplements and Supply Chain Committees. ... in the consumer goods industry, it can be difficult for companies to navigate, ...
Breaking Medicine News(10 mins):Health News:Insight Product Development Startup Competition on Track to Double Program Impact 2Health News:Insight Product Development Startup Competition on Track to Double Program Impact 3Health News:Missed Connections in Metro Denver Transit 2Health News:The Providence Fertility Center to Host Fertility Cocktail Hour on October 8, 2015 at Waterman Grille for Women Who Wish to Learn About Their Fertility and Egg Freezing 2Health News:Georgia Insurance Advisors Inaugurates Charity Drive to Assist the Family of Young Local Girl Diagnosed with an Enlarged Heart 2Health News:Georgia Insurance Advisors Inaugurates Charity Drive to Assist the Family of Young Local Girl Diagnosed with an Enlarged Heart 3Health News:Inmar Experts To Address OTC Manufacturers’ Session on Hazardous Waste and Handling at CHPA Meeting 2Health News:Inmar Experts To Address OTC Manufacturers’ Session on Hazardous Waste and Handling at CHPA Meeting 3
... The Disabled American,Veterans (DAV) is commending lawmakers ... largest increase in funding for the Department of,Veterans ... Congress and the,Administration to support this important legislation ... Construction and Veterans Affairs Appropriations bill,calls for an ...
... The Netherlands, Nov. 6 Kiadis Pharma,announced today ... orphan drug,designation by the US Food and Drug ... prevention of Graft versus Host Disease (GvHD),following allogeneic ... clinical studies and anticipated to enter clinical phase ...
... Nov. 6 The American Public,Health Association today ... health issues from food safety and obesity to ... are descriptions of some of the various measures ... Annual Meeting in,Washington, D.C., Nov. 3-7. Full policies ...
... further underperformance and ... deterioration of shareholder value., ANAHEIM, Calif., ... health benefit and pension fund trustees and,administrators are in ... Plans conference. The conference is,considered a premier marketing opportunity ...
... Canadian researchers expect to accelerate the war on cancer by ... people who volunteer their idle computer time to tackle some ... team, led by Dr. Igor Jurisica at the Ontario Cancer ... Health Network, are the first from Canada to use the ...
... hepatitis C and advanced liver disease who did ... decreases in their liver enzymes, viral levels, and ... However, the treatment did not slow or prevent ... come from the clinical trial, Hepatitis C Antiviral ...
Cached Medicine News:Health News:VA Budget Earns High Praise 2Health News:FDA Grants Kiadis Pharma Lead Product ATIR Orphan Drug Designation 2Health News:FDA Grants Kiadis Pharma Lead Product ATIR Orphan Drug Designation 3Health News:APHA Adopts New Policies on Food Safety, Global Climate Change, Multidrug-Resistant Organisms, Breastfeeding and Feminine Hygiene 2Health News:APHA Adopts New Policies on Food Safety, Global Climate Change, Multidrug-Resistant Organisms, Breastfeeding and Feminine Hygiene 3Health News:APHA Adopts New Policies on Food Safety, Global Climate Change, Multidrug-Resistant Organisms, Breastfeeding and Feminine Hygiene 4Health News:Labor Union Coalition Alerts Industry Analysts About Rite Aid 2Health News:Labor Union Coalition Alerts Industry Analysts About Rite Aid 3Health News:IBM world community grid squeezes decades of cancer research into 2 years 2Health News:Hepatitis C treatment reduces the virus but serious liver problems may progress 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: